Moleculin Biotech Stock Price, News & Analysis (NASDAQ:MBRX) $0.61 +0.01 (+1.67%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.58▼$0.6150-Day Range$0.40▼$0.6252-Week Range$0.34▼$1.65Volume52,263 shsAverage Volume168,239 shsMarket Capitalization$18.18 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Moleculin Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,621.3% Upside$10.50 Price TargetShort InterestHealthy1.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.88) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector567th out of 949 stocksPharmaceutical Preparations Industry271st out of 442 stocks 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Moleculin Biotech has a forecasted upside of 1,621.3% from its current price of $0.61.Amount of Analyst CoverageMoleculin Biotech has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.00% of the outstanding shares of Moleculin Biotech have been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently increased by 59.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 2.4 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 1 article on an average week.Search Interest2 people have searched for MBRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 7.67% of the stock of Moleculin Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($0.88) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Moleculin Biotech Stock (NASDAQ:MBRX)Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesDecember 1, 2023 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)November 29, 2023 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comDecember 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 21, 2023 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.comNovember 14, 2023 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comMoleculin Biotech gains after early data for lead cancer therapyNovember 13, 2023 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | msn.comMoleculin Biotech Q3 GAAP EPS of -$0.19 beats by $0.03December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 13, 2023 | markets.businessinsider.comMoleculin Biotech Announces Positive Interim Data For Annamycin TrialsNovember 13, 2023 | benzinga.comPenny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38%November 13, 2023 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 MonthsNovember 13, 2023 | finance.yahoo.comMoleculin Reports Third Quarter 2023 Financial ResultsNovember 10, 2023 | msn.comMoleculin Biotech Q3 2023 Earnings PreviewNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)November 7, 2023 | finance.yahoo.comMoleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and WebcastNovember 6, 2023 | finance.yahoo.comMoleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung MetastasesOctober 11, 2023 | finance.yahoo.comMoleculin to Participate in the Virtual Investor Ask the CEO ConferenceOctober 2, 2023 | finance.yahoo.comMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)September 21, 2023 | finance.yahoo.comMoleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)September 18, 2023 | markets.businessinsider.comMoleculin Biotech Reports Independent Report Of No Cardiotoxicity In AnnamycinSeptember 18, 2023 | finance.yahoo.comMoleculin Announces New Positive Independent Report of No Cardiotoxicity in AnnamycinSeptember 15, 2023 | investorplace.comWhy Is Moleculin Biotech (MBRX) Stock Is Moving Today?September 14, 2023 | finance.yahoo.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingSeptember 5, 2023 | finance.yahoo.comMoleculin to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 12, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX)August 12, 2023 | finance.yahoo.comQ2 2023 Moleculin Biotech Inc Earnings CallSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$16.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,621.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.64% Return on Assets-53.85% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio7.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book0.52Miscellaneous Outstanding Shares29,810,000Free Float27,813,000Market Cap$18.18 million OptionableNot Optionable Beta1.89 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 63)Founder, Chairman, President & CEO Comp: $1.35MMr. Jonathan P. Foster CPA (Age 59)Executive VP & CFO Comp: $653.69kDr. Donald H. Picker Ph.D. (Age 77)Chief Scientific Officer Comp: $520.84kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. Robert C. Shepard FACP (Age 71)M.D., Chief Medical Officer of Annamycin Dr. John Paul Waymack M.D. (Age 71)Sc.D., Senior Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 68)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 61)Consultant Comp: $51.11kMr. Louis Ploth Jr. (Age 69)Independent Advisor Comp: $118.49kMore ExecutivesKey CompetitorsBullfrog AINASDAQ:BFRGIndaptus TherapeuticsNASDAQ:INDPFortress BiotechNASDAQ:FBIOEquilliumNASDAQ:EQTFF PharmaceuticalsNASDAQ:TFFPView All Competitors MBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price target for 2024? 2 equities research analysts have issued 1-year price targets for Moleculin Biotech's stock. Their MBRX share price targets range from $5.00 to $16.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,621.3% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2023? Moleculin Biotech's stock was trading at $1.06 at the beginning of the year. Since then, MBRX stock has decreased by 42.5% and is now trading at $0.61. View the best growth stocks for 2023 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 296,900 shares, an increase of 59.7% from the October 31st total of 185,900 shares. Based on an average daily trading volume, of 155,000 shares, the short-interest ratio is presently 1.9 days. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Friday, August, 11th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. During the same period in the previous year, the company posted ($0.24) EPS. When did Moleculin Biotech's stock split? Moleculin Biotech shares reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MBRX) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.